| Name | Title | Contact Details |
|---|
Patient Comfort Systems is a Newark, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At California Hospital Association (CHA), we collaborate with our members to provide strong and effective representation and advocacy to advance the interests of California hospitals, patients and communities. CHA is a trusted resource, working with members to achieve legislative, regulatory, and legal accomplishments at the state and federal level. Based in Sacramento, CHA is the statewide leader representing the interests of more than 400 hospitals and health systems in California.
Wisdo is an award-winning social health and clinical referral platform that addresses the adverse consequences of social isolation and loneliness on the mental and physical health of 124 million Americans. Research shows that Wisdo results in $1,900+ in annual medical cost savings, a 37% reduction in depression, a 34% increase in the number of healthy days experienced by our members, and an 80% retention rate on month 12. More than 1 million adults have joined the Wisdo community, where they realized measurable improvements in their health through community-driven social support, professionally moderated group sessions, and when appropriate clinical referrals based on predictive analytics.
Clarity Child Guidance Center exists to transform the lives of children and families. We are the only nonprofit treatment center in San Antonio and South Texas that specializes in children ages 3-17 who suffer from serious mental health problems. Our inpatient and outpatient programs include a range of services, from crisis stabilization, to psychiatric evaluations, to ongoing therapy.
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.